YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	28.2M 9.2M 8M 7.44M 6.83M 12.9M 878M 13.1M 87.72M 34.43M 437M 34.54M 33.78M 1.47B	P/E 2024	-4.93x	P/E 2025	-9.22x
Enterprise Value	28.31M 9.24M 8.03M 7.47M 6.86M 12.96M 882M 13.16M 88.08M 34.57M 439M 34.68M 33.92M 1.47B	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.18%	Yield 2024 *	-	Yield 2025	-

05-03	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
11-13	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
10/09/25	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
01/09/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/07/24	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
27/03/24	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
27/03/24	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
31/08/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
26/03/23	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/08/21	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

26/02/21	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
18/01/21	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
18/01/21	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
15/12/20	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
19/11/20	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	31/03/2022
Oren Attiya DFI	Director of Finance/CFO	44	-
Daniel Spira AUD	Comptroller/Controller/Auditor	72	26/06/2019

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	09/12/2021
Shimon Bar-Kama BRD	Director/Board Member	74	04/12/2018
Varda Kalal BRD	Director/Board Member	58	14/02/2022

Cannassure Therapeutics Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation: Cannassure Therapeutics Ltd

Latest news : Cannassure Therapeutics Ltd

Press Releases: Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors: Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	9.2M
SUN HUNG KAI PROPERTIES LIMITED	+1.07%	+2.07%	+31.76%	+26.29%	45.53B
CHINA RESOURCES LAND LIMITED	-2.35%	+1.59%	+15.08%	-8.03%	30.19B
MITSUBISHI ESTATE CO., LTD.	-4.61%	-2.43%	+37.27%	+124.12%	29.4B
MITSUI FUDOSAN CO., LTD.	-3.17%	+0.65%	+14.83%	+60.36%	26.35B
EMAAR PROPERTIES	-0.54%	-0.72%	-27.87%	+62.72%	26.47B
CK ASSET HOLDINGS LIMITED	-1.44%	-0.13%	+32.70%	+6.31%	21.35B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	-2.70%	-2.09%	+30.03%	+89.33%	20.88B
ALPHA DHABI HOLDING	+1.53%	+0.27%	-41.16%	-63.33%	19.93B
CHINA OVERSEAS LAND & INVESTMENT LIMITED	-2.10%	+1.73%	-0.66%	-26.42%	18.86B
Average	-2.18%	+0.06%	+10.22%	+30.15%	26.55B
Weighted average by Cap.	-1.47%	+0.21%	+13.15%	+33.87%

	2024	2025
Net sales	76K 24.79K 21.55K 20.06K 18.41K 34.77K 2.37M 35.31K 236K 92.79K 1.18M 93.09K 91.05K 3.95M	-
Net income	-3.68M -1.2M -1.04M -970K -890K -1.68M -114M -1.71M -11.43M -4.49M -56.96M -4.5M -4.4M -191M	-3M -977K -849K -791K -726K -1.37M -93.28M -1.39M -9.32M -3.66M -46.44M -3.67M -3.59M -156M
Net Debt	980K 320K 278K 259K 237K 448K 30.51M 455K 3.05M 1.2M 15.19M 1.2M 1.17M 50.94M	115K 37.51K 32.61K 30.35K 27.86K 52.62K 3.58M 53.43K 358K 140K 1.78M 141K 138K 5.98M